Royalties from a breakthrough Australian cancer treatment are bolstering a new $66 million life sciences venture fund that has been aimed squarely at the local sector’s “broken” commercialisation link.
The Walter and Eliza Hall Institute of Medical Research (WEHI) this week unveiled its ten year ‘ 66ten’ fund, which has been operating quietly for the last 12 months and already backed rare disease-modifying treatments.
66ten is targeting scientific breakthroughs at WEHI or its work with partners, offering pre-seed and seed funding for an early equity stake it hopes will eventually fund more breakthroughs at Australia’s oldest medical research institute
Want to know how this story ends?
Become a subscriber for complete access to all stories on InnovationAus.com and our daily newsletter.
Do you know more? Contact James Riley via Email.